Among European countries, Switzerland has been able to position itself especially well as the home base for various foreign life science and medtech companies by creating an advantageous business environment. As a financial centre Switzerland, in particular, offers companies an international investor base whose focus is on the quality of a company rather than where it is from. Switzerland is a global leader in cross-border private banking and is one of Europe's leading financial centres for equity-investing institutions. Companies benefit from access to an international financial network, great placing power and the high visibility of each company.

In terms of investor relations, companies can only gain from Switzerland's geographical location and size. In particular, it is important to be able to reach investors quickly and efficiently. The close attention given by the media, analysts and investors to each company makes it easy for market participants to form an opinion on a one-to-one basis and also guarantees the necessary flow of information. Switzerland is a centre for sector-oriented institutional investors, especially in life sciences. These investors draw on many years of international experience in sector-oriented investing, which makes them particularly stimulating contacts.
Finally, Swiss law offers extraordinary incentives with respect to the sound growth of local companies. Labour law is some of the most liberal in the world and tax law – private and corporate – is very favourable.